News
23andMe sale reveals what your genetic data is worth. It’s less than you think
The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK made a $300 million dollar deal with 23andMe which allowed it to acquire the genetic data of 5 million people. That means the value of each customer’s data was about $60 at that time.
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...
Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...
Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...
Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...
Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.
The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...
Republican senators John Cornyn and Chuck Grassley and Democratic Sen. Amy Klobuchar are rolling out a bipartisan measure to protect sensitive genetic data in response to privacy concerns sparked by ...
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Missouri Attorney General Andrew Bailey is alerting residents after biotechnology company 23andMe filed for bankruptcy in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback